Physician profile
Jack D Sobel
NPI 1184664088
$18,236.81
in general payments reported to CMS, 2019-2025
7 companies · $14K in 2025
The $14K reported for 2025 was more than what 94% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $500 · 2021: $2,020 · 2022: $2,210 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $9,603 · Consulting Fee: $3,000 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $750 · Food and Beverage: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $9,602.91 |
| Consulting Fee | $3,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $750.00 |
| Food and Beverage | $153.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mycovia Pharmaceuticals, INC. | $13,352.91 | 2025 | Vivjoa |
| Scynexis, INC. | $2,210.48 | 2022 | |
| Biofire Diagnostics, LLC | $1,520.00 | 2021 | |
| New American Therapeutics, INC. | $500.00 | 2021 | |
| Amag Pharmaceuticals, INC. | $500.00 | 2020 | |
| Melinta Therapeutics, LLC | $119.45 | 2025 | Rezzayo |
| Dendreon Pharmaceuticals LLC | $33.97 | 2025 | Provenge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Sobel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.